ABSTRACT: Introduction: Electrical impedance myography (EIM) is a noninvasive technique for measuring muscle composition and a potential physiological biomarker for facioscapulohumeral muscular dystrophy (FSHD). Methods: Thirty-two participants with genetically confirmed and clinically affected FSHD underwent EIM in 7 muscles bilaterally. Correlations between EIM and baseline clinical measures were used to select EIM variables of interest in FSHD, and EIM and clinical measures were followed for 1 year. Results: There were no significant changes in the EIM variables. Although 50-kHZ reactance correlated the strongest with clinical measures at baseline, the 50-211-kHZ phase ratio demonstrated lower within-subject 12-month variability, potentially offering sample size savings for FSHD clinical trial planning. Discussion: EIM did not identify significant disease progression over 12 months. It is currently unclear whether this is because of limitations of the technology or the slow rate of disease progression in this cohort of FSHD patients over this period of time.
Facioscapulohumeral muscular dystrophy (FSHD)
is a hereditary muscle disorder. 1, 2 A unifying model of the genetic mechanism for FSHD has been proposed, and increasing knowledge of the pathogenic mechanism provides opportunities to develop targeted therapeutic strategies. 3, 4 Therefore, there is a high likelihood that clinical trials will be initiated in the upcoming years. In preparation for these trials, there is a requirement to develop outcome measures. 5 Development of biomarkers that are sensitive to change will be crucial, especially for early phase clinical trials.
Electrical impedance myography (EIM) has been proposed as a biomarker for disease severity and progression in neuromuscular disorders. 6, 7 EIM is a noninvasive technique that measures changes in muscle composition through bioimpedance measures and thus provides a potential quantitative assessment of structural muscle changes. 6 Electrodes are placed on the skin that produce multifrequency, low-intensity alternating electrical currents. These currents are applied to individual muscles or muscle groups, and the resulting voltage is measured. Impedance is a measure of obstruction of the flow of the electrical current through the tissue, which differs between various body tissues such as muscle or fat.
In FSHD, muscles undergo structural changes as the disease progresses, including atrophy, fatty infiltration, edema, and fibrosis. These changes can all influence the impedance across the muscle tissue. 8, 9 In a previous cross-sectional study on EIM in FSHD, we showed that EIM is a reliable measure of muscle composition in FSHD that correlates with functional outcome measures. 10 Studies on other neuromuscular disorders such as amyotrophic lateral sclerosis, congenital myopathies, and Duchenne muscular dystrophy have shown that EIM is able to capture changes over time, [11] [12] [13] [14] although research is ongoing regarding what variables are most suitable to use in each different disorder.
In this study we assessed the changes in EIM measurements in FSHD participants and the potential of EIM as a biomarker for clinical trials using a 1-year longitudinal study.
MATERIALS AND METHODS
Study Design. This was a prospective, observational study. Participants were recruited at the University of Rochester Medical Center from 2012 to 2015. The study was approved by the human subjects committee, and written informed consent was obtained from all participants.
Participants. We included genetically confirmed participants, aged 18-75 years, who had clinical symptoms while still being ambulatory. 10 Data were obtained during 3 visits, 1 at baseline (and < 3 weeks later for reliability testing), 1 at 6 months, and 1 at 12 months. Baseline and reliability data have previously been reported. 10 EIM Measurements. EIM measurements were obtained by using a handheld EIM device (Skulpt, Boston, Massachusetts) with a transverse sensor configuration (current passing across the myofibers), as previously described. 10 Measurements were obtained by using standard positioning over the following muscles bilaterally: deltoid, biceps, triceps, abdominals, vastus lateralis, tibialis anterior, and thoracic paraspinals. Investigators underwent a single afternoon training session at the beginning of the study. Reactance, resistance, and phase angle were recorded for 41 frequencies ranging from 1 kHZ to 10 MHZ. For each muscle, 3 consecutive measurements were performed, and the 2 most closely aligned measurements were averaged. For analyses, 4 different frequencies, 50, 100, 211, and 300 kHZ, were chosen on the basis of prior EIM studies in neuromuscular diseases. In addition, phase ratios were calculated for 50/211 kHZ and 100/300 kHZ.
11,15
Clinical Outcome Measures. Quantitative strength measurements were collected by using fixed dynamometry (QMA system; Aeverl Medical, Gainesville, GA). The maximum voluntary isometric contraction testing (MVICT) was recorded in kilogram force for each muscle group and then standardized for sex, age, and height, as previously described. 16 Composite MVICT scores were calculated by averaging the standardized scores across multiple muscle groups: shoulder abduction, elbow flexors and extensors, ankle dorsiflexors, knee flexors and extensors, and handgrip. Regional composite scores were calculated by averaging upper and lower extremity muscle groups only.
The FSHD clinical score assigns severity scores for different body regions, resulting in a total score that ranges from 0 to 15, in which zero indicates no symptoms and 15 indicates extremely severe symptoms (e.g., requiring a wheelchair for mobility). The "timed up and go test" is a timed functional test that uses the time it takes for a patient to get up from a standard armchair, walk 3 meters, turn, walk back, and sit down. 17 The domain delta questionnaire is a patient-reported anchor questionnaire that asks participants to indicate whether they became worse, remained stable, or improved during the study period according to the domains of overall health, mobility and ambulation, and upper arm and shoulder function. There is 1 question for each domain, with 5 response options: much worse, a little worse, unchanged, a little better, or much better. 18 Statistical Analysis. Statistical analysis was performed in SPSS version 22 (IBM, Armonk, NY). Descriptive statistics were calculated for all variables and are presented as mean 6 standard deviation unless stated otherwise. Outliers resulting from technical EIM errors, such as negative values at low frequencies or extremely high values far outside the normal range, were not included in analysis (the combination of deleted outliers and missing data resulted in no more than 1.4% of total data being missing). Missing values were considered to be missing at random. For analysis of average scores over multiple muscles, we used a lastobservation-carried-forward approach for missing data.
Spearman q analysis was used to calculate bivariate correlations, and P < 0.05 was considered statistically significant. A one-way repeated-measures analysis of variance (ANOVA) was used to test for changes in EIM and clinical results at baseline and after 6 and 12 months. To control for multiple testing, we applied the Benjamini-Hochberg false discovery rate procedure, a less conservative method than the Bonferroni correction, in which we accepted the proportion of false discoveries to be 5%. 19 Differences in change in EIM outcomes between participants that subjectively did or did not progress over 6 months according to the domain delta questionnaire were tested by using a mixed ANOVA, with time as a withinsubject factor and outcome on the domain delta questionnaire as a between-subject factor. Sample size calculations were based on a hypothetical 2-armed placebo-controlled clinical trial with an 80% power to detect a 5% difference. G*Power statistical software version 3.1 (Heinrich-HeineUniversit€ at D€ usseldorf; http://www.gpower.hhu.de/en. html) was used to calculate sample sizes on the basis of the mean baseline EIM values and the standard deviation of the 12 month change. 20 
RESULTS
Participants. Among the previously reported 35 participants in our cross-sectional EIM study, 10 32 participants had 12-month longitudinal data available for analysis. The majority of participants were men. Baseline characteristics are shown in Table 1 EIM Changes. After 12 months of follow-up, no significant changes in EIM variables were found for the average of all muscles that were measured or for the average of lower or upper extremity muscles. Mean changes over 12 months in 50-kHZ reactance and 50-211-kHZ phase ratio, 2 of the EIM variables that correlated the strongest with clinical measures at baseline, are shown in Figure 1 . The mean change of the 50-kHZ reactance over all muscles that were measured was 0.001 after 12 months (95% CI 0.309-0.312), and, for the 50-211-kHZ phase ratio, the mean 12 month change was 0.009 (95% CI 20.015-0.034). In addition, we assessed changes in 50-kHZ reactance and 50-211-kHZ phase ratio over 12 months for all individual muscles and found no significant changes (Supp. Info. Table 2 ). We also assessed 12-month changes in individual muscles for the reactance and phase for 100-, 211-, and 300-kHZ and for the 100-300-kHZ phase ratio and found no significant changes (data not reported). Table 2 . These estimates of variability were used to calculate the required sample sizes for a 2-armed placebo-controlled clinical trial with an 80% power to detect a 5% difference over 12 months. The variability across phase ratio measures was smaller compared with reactance measures and with clinical measures, resulting in smaller sample sizes, with the phase ratio as a potential outcome variable (Table 2) .
DISCUSSION
In this 12-month follow-up study of 32 participants with FSHD, EIM measurements did not change. The absence of change was consistent across all EIM variables, all frequencies, and all (individual) muscles that were measured. There was a small decrease in the composite MVICT for all muscles that were measured, and there was no change in the strength measurements for individual muscles or in the timed up and go test, indicating that this select group of patients showed only minimal change over 1 year. This fits with the clinical picture of FSHD as a slowly progressive disorder with functional decline gradually evolving over many years. 16 Because of the small or even absent change in the clinical outcome measures, it is not possible to conclude definitively whether the absence of change in EIM variables was the result of limitations of this technology as a longitudinal biomarker in this population over this period of time versus the possibility that EIM is a sufficient tool that detected no change in a clinically relatively static subset of patients. On a cross-sectional level, there is a moderate correlation of EIM measurements with clinical measures, especially for 50-kHZ reactance, indicating that EIM is able to capture differences in the degree of muscle involvement. 10 We analyzed data both on individual muscles or muscle groups and on composite scores. Although composite scores have the advantage of smaller variability, the addition of relatively unaffected muscles can decrease the chance of detecting a change. The muscles that were measured by EIM in this study were all shown in imaging studies on FSHD to be commonly affected. [21] [22] [23] In future studies, including the hamstrings could be a valuable addition because these are affected frequently and early in the disease course. 22 This study measured EIM variables only in the setting of a natural history study. Therefore, EIM could be a useful biomarker in clinical trials in which therapeutic interventions may have a beneficial effect on the muscles. For example, in boys with Duchenne muscular dystrophy, a change in EIM values was seen shortly after initiating corticosteroid treatment. 24 FIGURE 2. Change in electrical impedance myography variables (50-kHZ reactance and 50-211-kHZ phase ratio) after 12 months for patients who reported that they had remained stable and who reported subjective disease progression on different domains of the domain delta questionnaire. It is still unclear which EIM variables are best suited to measure changes, and the choice for a specific variable depends on the disease being studied. Consequently, multiple studies have used different outcomes including, among others, single and multifrequency measures, single muscle and composite measures, single phase values, and phase ratios. 11, [13] [14] [15] 25 Prior studies have shown that reactance is least susceptible to variability in subcutaneous fat content or electrode configuration. 26 Despite this, several studies have used phase ratios rather than reactance; this value appears to be optimized for function versus subcutaneous fat in muscle disease and, as a derived measure, uses both elements of reactance and resistance. 24, 27 For FSHD, the reactance correlated the strongest with clinical measures at baseline and seemed least affected by changes in body fat, which is also reflected in the weaker correlations with the body mass index. However, because of the smaller variability in phase ratio outcomes, this variable would require much smaller samples to detect differences in a clinical trial. Therefore, the choice of the variable to be used in FSHD will depend on the clinical trial design in which a trade-off should be made between the stronger correlation with clinical measures of 50-kHZ reactance and the opportunity to use smaller samples with the 50-211-kHZ phase ratio. In addition, the use of the 50-211-kHZ EIM variable would permit smaller samples compared with the clinical measures. The required sample sizes for standardized quantitative muscle testing are consistent with a natural history study on FSHD that used samples of 160 patients per group for a 2-armed clinical trial with 1-year of follow-up. 16 For future studies, there would be different ways to increase the chance of detecting changes with EIM measurements. First, a larger cohort, a longer follow-up period, or a subset of patients with a more rapid progression could result in differences that can be picked up by EIM. Additionally, advances in the sensor technology make different electrode configurations possible by using the same sensor (e.g., longitudinal vs. cross sectional or a combination of the 2). 28 This was a single-site study, and, for EIM to be used in future studies on FSHD, its results should be validated in a multicenter cohort. To assess changes over time, we used a repeated-measure ANOVA. Another commonly used option for longitudinal studies is a linear mixed-effects model. Because the design of this study was simple and there were few data points missing, the results of both analyses including the sample size calculations are expected to be similar. We did not include a healthy control group and, therefore, do not know how longitudinal EIM data would compare to healthy controls.
Although EIM did not identify statistically significant changes in this FSHD cohort, it is an easily applied, fast, and noninvasive technique that provides quantitative measures of muscle composition that can result in sample size savings for clinical trials. Therefore, assessment of its sensitivity to change in larger cohorts or over a longer follow-up period should be considered.
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